Payment overview · 2025
General Payments
$27.50
1 reported records · 1 companies
Healthcare provider profile · identity verified
Ashraf S Mostafa, MD
Allopathic & Osteopathic Physicians|Internal Medicine · TOWSON, MD · NPI 1033279625
Verified facts
What the public records show
CMS Open Payments records show Ashraf S Mostafa, MD received $27.50 in general payments during 2025 across 1 reported records.
Novo Nordisk Inc accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.50 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $27.50 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Wegovy Normalized: wegovy |
Drug | Novo Nordisk Inc | $27.50 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Eliquis | Apixaban | 371 | 38 |
| Atorvastatin Calcium | Atorvastatin Calcium | 239 | 61 |
| Furosemide | Furosemide | 232 | 55 |
| Levothyroxine Sodium | Levothyroxine Sodium | 195 | 34 |
| Pantoprazole Sodium | Pantoprazole Sodium | 187 | 49 |
| Clopidogrel | Clopidogrel Bisulfate | 176 | 34 |
| Montelukast Sodium | Montelukast Sodium | 172 | 40 |
| Metoprolol Succinate | Metoprolol Succinate | 162 | 39 |
| Tamsulosin Hcl | Tamsulosin Hcl | 156 | 30 |
| Amlodipine Besylate | Amlodipine Besylate | 151 | 38 |
| Escitalopram Oxalate | Escitalopram Oxalate | 150 | 23 |
| Sertraline Hcl | Sertraline Hcl | 139 | 19 |
| Lisinopril | Lisinopril | 129 | 33 |
| Losartan Potassium | Losartan Potassium | 127 | 38 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 122 | 16 |
| Gabapentin | Gabapentin | 122 | 26 |
| Mirtazapine | Mirtazapine | 110 | 18 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 110 | 28 |
| Duloxetine Hcl | Duloxetine Hcl | 99 | 15 |
| Azithromycin | Azithromycin | 98 | 60 |
| Potassium Chloride | Potassium Chloride | 91 | 25 |
| Omeprazole | Omeprazole | 88 | 25 |
| Tramadol Hcl | Tramadol Hcl | 88 | 26 |
| Trazodone Hcl | Trazodone Hcl | 85 | 19 |
| Metoprolol Tartrate | Metoprolol Tartrate | 78 | 19 |
| Alprazolam | Alprazolam | 71 | 29 |
| Ipratropium-Albuterol | Ipratropium/Albuterol Sulfate | 70 | 16 |
| Pregabalin | Pregabalin | 67 | 16 |
| Hydralazine Hcl | Hydralazine Hcl | 66 | 19 |
| Clonidine | Clonidine | 65 | 17 |
| Protonix | Pantoprazole Sodium | 65 | suppressed |
| Metformin Hcl Er | Metformin Hcl | 64 | 19 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 63 | 36 |
| Carvedilol | Carvedilol | 61 | 20 |
| Buspirone Hcl | Buspirone Hcl | 59 | 13 |
| Metformin Hcl | Metformin Hcl | 59 | 16 |
| Fluticasone Propionate | Fluticasone Propionate | 58 | 22 |
| Warfarin Sodium | Warfarin Sodium | 57 | suppressed |
| Trulicity | Dulaglutide | 54 | suppressed |
| Divalproex Sodium | Divalproex Sodium | 52 | suppressed |
| Meloxicam | Meloxicam | 52 | 25 |
| Carbidopa-Levodopa | Carbidopa/Levodopa | 48 | suppressed |
| Latanoprost | Latanoprost | 48 | suppressed |
| Cefdinir | Cefdinir | 47 | 31 |
| Ertapenem | Ertapenem Sodium | 46 | suppressed |
| Jardiance | Empagliflozin | 45 | suppressed |
| Enulose | Lactulose | 44 | suppressed |
| Atenolol | Atenolol | 42 | 11 |
| Enoxaparin Sodium | Enoxaparin Sodium | 42 | suppressed |
| Simvastatin | Simvastatin | 42 | 11 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 41 | 21 |
| Nifedipine Er | Nifedipine | 41 | 11 |
| Allopurinol | Allopurinol | 40 | 11 |
| Amiodarone Hcl | Amiodarone Hcl | 39 | suppressed |
| Clonazepam | Clonazepam | 39 | suppressed |
| Dextrose 5%-0.45% Nacl | Dextrose 5 %-0.45 % Sod Chlord | 39 | 15 |
| Finasteride | Finasteride | 39 | suppressed |
| Famotidine | Famotidine | 38 | 11 |
| Lorazepam | Lorazepam | 38 | suppressed |
| Ceftriaxone | Ceftriaxone Sodium | 37 | 15 |
| Olanzapine | Olanzapine | 37 | suppressed |
| Quetiapine Fumarate | Quetiapine Fumarate | 36 | suppressed |
| Risperidone | Risperidone | 35 | suppressed |
| Tradjenta | Linagliptin | 35 | suppressed |
| Citalopram Hbr | Citalopram Hydrobromide | 34 | suppressed |
| Nebivolol Hcl | Nebivolol Hcl | 34 | suppressed |
| Primidone | Primidone | 34 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 33 | 20 |
| Glimepiride | Glimepiride | 32 | suppressed |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 32 | suppressed |
| Sodium Chloride | 0.9 % Sodium Chloride | 32 | 20 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 30 | 22 |
| Sucralfate | Sucralfate | 30 | suppressed |
| Cephalexin | Cephalexin | 29 | 13 |
| Clindamycin Hcl | Clindamycin Hcl | 29 | 12 |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 29 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 29 | suppressed |
| Colchicine | Colchicine | 28 | suppressed |
| Glipizide Er | Glipizide | 28 | suppressed |
| Combivent Respimat | Ipratropium/Albuterol Sulfate | 27 | suppressed |
| Clonidine Hcl | Clonidine Hcl | 26 | suppressed |
| Hydrochlorothiazide | Hydrochlorothiazide | 25 | suppressed |
| Mupirocin | Mupirocin | 25 | 16 |
| Oxycodone Hcl | Oxycodone Hcl | 25 | suppressed |
| Pravastatin Sodium | Pravastatin Sodium | 25 | suppressed |
| Prednisone | Prednisone | 25 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 24 | suppressed |
| Xarelto | Rivaroxaban | 24 | suppressed |
| Constulose | Lactulose | 23 | suppressed |
| Levetiracetam | Levetiracetam | 23 | suppressed |
| Memantine Hcl | Memantine Hcl | 23 | suppressed |
| Spironolactone | Spironolactone | 23 | suppressed |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 23 | 12 |
| Chlorhexidine Gluconate | Chlorhexidine Gluconate | 22 | 12 |
| Januvia | Sitagliptin Phosphate | 22 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 21 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 21 | suppressed |
| Doxycycline Hyclate | Doxycycline Hyclate | 21 | 13 |
| Sodium Chloride | Sodium Chloride 0.45 % | 21 | 11 |
| Synthroid | Levothyroxine Sodium | 21 | suppressed |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 20 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Breo Ellipta | Fluticasone/Vilanterol | 19 | suppressed |
| Carbamazepine | Carbamazepine | 19 | suppressed |
| Pramipexole Dihydrochloride | Pramipexole Di-Hcl | 19 | suppressed |
| Lactulose | Lactulose | 18 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 18 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 18 | suppressed |
| Torsemide | Torsemide | 18 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 17 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 17 | 13 |
| Donepezil Hcl | Donepezil Hcl | 17 | suppressed |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 17 | suppressed |
| Amantadine | Amantadine Hcl | 16 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 16 | suppressed |
| Ezetimibe | Ezetimibe | 16 | suppressed |
| Levalbuterol Hcl | Levalbuterol Hcl | 16 | suppressed |
| Baclofen | Baclofen | 15 | suppressed |
| Calcium Acetate | Calcium Acetate | 15 | suppressed |
| Novolog Flexpen | Insulin Aspart | 15 | suppressed |
| Nystatin | Nystatin | 15 | suppressed |
| Ropinirole Hcl | Ropinirole Hcl | 15 | suppressed |
| Zolpidem Tartrate | Zolpidem Tartrate | 15 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 14 | suppressed |
| Flecainide Acetate | Flecainide Acetate | 14 | suppressed |
| Fluconazole | Fluconazole | 14 | suppressed |
| Folic Acid | Folic Acid | 14 | suppressed |
| Metronidazole | Metronidazole | 14 | 13 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 14 | suppressed |
| Cefepime Hcl | Cefepime Hcl | 13 | suppressed |
| Colestipol Hcl | Colestipol Hcl | 13 | suppressed |
| Erythromycin | Erythromycin Base | 13 | suppressed |
| Paxlovid | Nirmatrelvir/Ritonavir | 13 | 13 |
| Clotrimazole | Clotrimazole | 12 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 12 | suppressed |
| Fluoxetine Hcl | Fluoxetine Hcl | 12 | suppressed |
| Nuedexta | Dextromethorphan Hbr/Quinidine | 12 | suppressed |
| Piperacillin-Tazobactam | Piperacillin Sodium/Tazobactam | 12 | suppressed |
| Spiriva Handihaler | Tiotropium Bromide | 12 | suppressed |
| Abrysvo | Rsv Vacc, Pref A And Pref B/Pf | 11 | 11 |
| Bupropion Hcl | Bupropion Hcl | 11 | suppressed |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 11 | suppressed |
| Isosorbide Dinitrate | Isosorbide Dinitrate | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $27.50 · 1 records | Novo Nordisk Inc | Wegovy | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error